Several clinical studies have found that obese patients have impaired basal and postprandial GLP-1 secretion compared to normal-weight patients (58, 59)
Studies show that patients who stop GLP-1 medications without a transition plan regain 50% of lost weight within one year, though individual outcomes vary based on lifestyle and genetic factors
Meanwhile, Eli Lilly has not yet filed for approval of its oral GLP-1, orforglipron, but the company is preparing to do so by the end of the year
Consistency is key, and stopping early may reduce benefits
Instead of absorbing the full cost of repeat prescriptions, you recover part of what you spend each year, helping to keep your overall healthcare budget under control
Analgesics and sedatives in critically ill newborns and infants: the impact on long-term neurodevelopment